I read the clinical trial registration and it seems like there's a lot of Goodharting going on when you pass this off as a cure for COVID-19.
From the preregistration it's interesting what endpoints they have. The primary endpoint is "Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity".
That sounds to me like the idea is if you put the stuff in your nasal pathways then you kill the virus in the nasal pathways and as a result it's less likely that you infect other people.
In the list they have as outcomes:
3. To Measure the efficacy of NONI in prevention of progression of COVID-19 [ Time Frame: 28 days ]
Measure the proportion of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms
4. To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19 [ Time Frame: 6 days ]
5. To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19
The press release doesn't seem to indicate that they found a statistical significant result on either of those outcomes and I would expect that they would have put it into the press release if they found it.
This suggests the treatment might make you less infectious to other people but at the same time it doesn't provide clinical benefits to the person being treated.
It might be clinically useful to be able to reduce the infectiousness of patients but that's far from a cure for COVID-19.